Balversa (Erdafitinib) Patent Expiration, LOE Window & CMS Spending
Balversa (Erdafitinib) by Johnson & Johnson: FDA Orange Book core substance LOE 2033-04-12 (last listed 2038-02-02), 0 AB generics, $27.0M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N212018 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-04-12 |
| Last Listed Patent or Exclusivity Date | 2038-02-02 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $27.0M |
| 2024 Medicare Part D Spend | $22.7M |
| 2024 Medicaid Spend | $4.3M |
| Reported Wholesale Price Change (CA SB 17) | 15 WAC filings (max 22.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.